In our daily work in a company or freelance setting, we interact with other relevant functions, typically biostatistical, medical, programming, and data management colleagues, so that we can deliver wellrounded deliverables that take account of multiple perspectives. If we take a higher-level strategic view for the developing regulatory public disclosure (RPD) arena, then we should be talking to professionals outside of our usual networks to ensure we understand and take account of broader perspectives. I engaged with Cathal Gallagher of EMA’s Technical Anonymisation Group and asked him the kinds of questions that you as medical writers might, and hope to have contextualised his RPD perspectives to our work in writing clinical documents fit for public disclosure.